Publications in collaboration with researchers from Hospital Universitario Virgen de las Nieves (20)

2022

  1. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

    npj Genomic Medicine, Vol. 7, Núm. 1

2020

  1. A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease

    Scientific Reports, Vol. 10, Núm. 1

  2. Recommendations of the Spanish Rheumatology Society for Primary Antiphospholipid Syndrome. Part I: Diagnosis, Evaluation and Treatment

    Reumatologia Clinica, Vol. 16, Núm. 2P1, pp. 71-86

  3. Recommendations of the Spanish Rheumatology Society for Primary Antiphospholipid Syndrome. Part II: Obstetric Antiphospholipid Syndrome and Special Situations

    Reumatologia Clinica, Vol. 16, Núm. 2P2, pp. 133-148

2019

  1. GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways

    Nature Communications, Vol. 10, Núm. 1

2018

  1. Association of a rare variant of the TNFSF13B gene with susceptibility to Rheumatoid Arthritis and Systemic Lupus Erythematosus

    Scientific Reports, Vol. 8, Núm. 1

2016

  1. LILRA3 deficiency is not involved in the giant cell arteritis and systemic sclerosis predisposition

    Clinical and Experimental Rheumatology

2015

  1. Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis

    Clinical and Experimental Rheumatology, Vol. 33, pp. 31-35

  2. Variability in the prescription of non-biologic disease-modifying antirheumatic drugs for the treatment of spondyloarthritis in Spain

    Seminars in Arthritis and Rheumatism, Vol. 44, Núm. 6, pp. 633-640

2014

  1. A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility

    Arthritis Research and Therapy, Vol. 16, Núm. 1

  2. Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: A systematic review

    Seminars in Arthritis and Rheumatism, Vol. 44, Núm. 2, pp. 175-185

2013

  1. Implication of IL-2/IL-21 region in systemic sclerosis genetic susceptibility

    Annals of the Rheumatic Diseases, Vol. 72, Núm. 7, pp. 1233-1238

2012

  1. Analysis of the association between CD40 and CD40 ligand polymorphisms and systemic sclerosis

    Arthritis Research and Therapy, Vol. 14, Núm. 3

  2. Evaluation of a shared autoimmune disease-associated polymorphism of TRAF6 in systemic sclerosis and giant cell arteritis

    Journal of Rheumatology, Vol. 39, Núm. 6, pp. 1275-1279

  3. Influence of the IL6 gene in susceptibility to systemic sclerosis

    Journal of Rheumatology, Vol. 39, Núm. 12, pp. 2294-2302

2011

  1. No evidence for association between the CCR5/Delta32CCR5 polymorphism and systemic sclerosis

    Clinical and Experimental Rheumatology

2009

  1. Genetic variation in the nuclear factor κB pathway in relation to susceptibility to rheumatoid arthritis

    Annals of the Rheumatic Diseases, Vol. 68, Núm. 4, pp. 579-583

  2. Lack of association with rheumatoid arthritis of selected polymorphisms in 4 candidate genes: CFH, CD209, Eotaxin-3, and MHC2TA

    Journal of Rheumatology, Vol. 36, Núm. 8, pp. 1590-1595

2008

  1. Association of interferon regulatory factor 5 haplotypes, similar to that found in systemic lupus erythematosus, in a large subgroup of patients with rheumatoid arthritis

    Arthritis and Rheumatism, Vol. 58, Núm. 5, pp. 1264-1274

2006

  1. Registrolesaf. Características de los pacientes con lupus eritematoso sistémico síndrome antifosfolipídico registrados por usuarios médicos especialistas en reumatología y medicina interna

    Reumatologia Clinica, Vol. 2, Núm. 3, pp. 131-136